Literature DB >> 8969186

Efflux of cellular cholesterol and phospholipid to apolipoprotein A-I mutants.

D Sviridov1, L E Pyle, N Fidge.   

Abstract

Human plasma apolipoprotein A-I (apoA-I) and recombinant full-length proapoA-I (apoA-I-(-6-243)) as well as four truncated forms of proapoA-I were used as acceptors to study cholesterol and phospholipid efflux from HepG2 cells. Efflux of both cholesterol and phospholipid to the lipid-free plasma apoA-I was twice that of apoA-I-(-6-243). When apoA-I was incorporated into reconstituted high density lipoprotein, cholesterol efflux increased, phospholipid efflux decreased and the difference between plasma apoA-I and apoA-I-(-6-243) disappeared. Truncation of recombinant apoA-I to residues 222 (apoA-I-(-6-222)) and 210 (apoA-I-(-6-210)) resulted in a 70-95% decrease in their ability to promote the efflux of both intracellular and plasma membrane cholesterol. Further truncation to residues 150 (apoA-I-(-6-150)) and 135 (apoA-I-(-6-135)) fully restored the ability of apoA-I to promote cholesterol efflux. Phospholipid efflux closely paralleled the efflux of cholesterol. Interaction of 125I-labeled apoA-I with the cells was similar for apoA-I-(-6-243), apoA-I-(-6-222), and apoA-I-(-6-210), but slightly higher for apoA-I-(-6-150) and apoA-I-(-6-135). When complexed with phospholipid, all forms except apoA-I-(-6-210) formed discoidal reconstituted high density lipoprotein particles. When the same amounts of free or lipid-associated apoA-I were compared, association of apoA-I with phospholipid increased cholesterol efflux and decreased phospholipid efflux, and the difference in the ability of different mutants to promote cholesterol and phospholipid efflux disappeared. We conclude that the capacity of lipid-free apoA-I to promote cholesterol efflux is related to its ability to mobilize cellular phospholipid, which apparently involves a region around residues 222-243. A second lipid-binding region is exposed when the carboxyl-terminal half of apoA-I is absent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8969186     DOI: 10.1074/jbc.271.52.33277

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini.

Authors:  Ivano Eberini; Laura Calabresi; Robin Wait; Gabriella Tedeschi; Angela Pirillo; Lina Puglisi; Cesare R Sirtori; Elisabetta Gianazza
Journal:  Biochem J       Date:  2002-03-15       Impact factor: 3.857

2.  Maturation of apolipoprotein A-I: unrecognized health benefit or a forgotten rudiment?

Authors:  Dmitri Sviridov
Journal:  J Lipid Res       Date:  2009-03-30       Impact factor: 5.922

3.  Cubbing in proapolipoprotein maturation.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  J Lipid Res       Date:  2011-09-06       Impact factor: 5.922

4.  Influence of apolipoprotein (Apo) A-I structure on nascent high density lipoprotein (HDL) particle size distribution.

Authors:  Charulatha Vedhachalam; Palaniappan Sevugan Chetty; Margaret Nickel; Padmaja Dhanasekaran; Sissel Lund-Katz; George H Rothblat; Michael C Phillips
Journal:  J Biol Chem       Date:  2010-08-02       Impact factor: 5.157

Review 5.  The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations.

Authors:  L Tian; M Fu
Journal:  J Endocrinol Invest       Date:  2011-06       Impact factor: 4.256

6.  Cholesterol transport between red blood cells and lipoproteins contributes to cholesterol metabolism in blood.

Authors:  Ryunosuke Ohkawa; Hann Low; Nigora Mukhamedova; Ying Fu; Shao-Jui Lai; Mai Sasaoka; Ayuko Hara; Azusa Yamazaki; Takahiro Kameda; Yuna Horiuchi; Peter J Meikle; Gerard Pernes; Graeme Lancaster; Michael Ditiatkovski; Paul Nestel; Boris Vaisman; Denis Sviridov; Andrew Murphy; Alan T Remaley; Dmitri Sviridov; Minoru Tozuka
Journal:  J Lipid Res       Date:  2020-09-09       Impact factor: 5.922

7.  Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties.

Authors:  A Hoang; A J Murphy; M T Coughlan; M C Thomas; J M Forbes; R O'Brien; M E Cooper; J P F Chin-Dusting; D Sviridov
Journal:  Diabetologia       Date:  2007-06-20       Impact factor: 10.122

8.  Antiretroviral compounds and cholesterol efflux from macrophages.

Authors:  Nigora Mukhamedova; Honor Rose; Huanhuan L Cui; Angela Grant; Urbain Tchoua; Anthony Dart; Michael Bukrinsky; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2009-03-21       Impact factor: 5.162

9.  Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo.

Authors:  Nigora Mukhamedova; Genevieve Escher; Wilissa D'Souza; Urbain Tchoua; Angela Grant; Zigmund Krozowski; Michael Bukrinsky; Dmitri Sviridov
Journal:  J Lipid Res       Date:  2008-07-12       Impact factor: 5.922

10.  A Systematic Investigation of Structure/Function Requirements for the Apolipoprotein A-I/Lecithin Cholesterol Acyltransferase Interaction Loop of High-density Lipoprotein.

Authors:  Xiaodong Gu; Zhiping Wu; Ying Huang; Matthew A Wagner; Camelia Baleanu-Gogonea; Ryan A Mehl; Jennifer A Buffa; Anthony J DiDonato; Leah B Hazen; Paul L Fox; Valentin Gogonea; John S Parks; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2016-01-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.